Merck (MRK) Stock Rises as EU Advisers Back Expanded Approval for RSV Drug ENFLONSIA
Key Takeaways
- •The EMA's CHMP issued a positive opinion recommending an expanded indication for ENFLONSIA covering children under 24 months at increased risk of severe RSV infection through a second season.
- •The European Commission is expected to decide on the expanded indication within two months, and a single approval would take effect across the EU, Iceland, Liechtenstein, and Norway.
- •The proposed expansion targets children vulnerable to serious respiratory illness due to chronic lung disease, congenital heart disease, or complications from premature birth.
- •Merck's European filing rests on the Phase 3 SMART trial, in which 502 participants received ENFLONSIA and 501 received monthly palivizumab during the first season, with 276 children given an additional 210 mg second-season dose.
- •ENFLONSIA is already approved in more than 55 countries, including the United States, Canada, China, and Japan, and the FDA has set March 22, 2027, as the target date for the parallel U.S. expansion application.

Merck & Co. (MRK) shares rose 0.65% to $147.90, gaining $0.95, after European regulators issued a positive opinion on an expanded indication for the company's respiratory syncytial virus (RSV) preventive treatment ENFLONSIA. RSV returns in seasonal waves each year, and widening the drug's approved population would extend preventive coverage to children whose underlying conditions leave them exposed after their first season. The stock recovered from intraday lows near $145.50 as buying activity strengthened during the session, and the recommendation brings Merck a step closer to expanding RSV prevention for high-risk children across Europe.
The positive opinion came from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which reviewed Merck's application to widen the approved use of ENFLONSIA. The CHMP's opinion represents the scientific assessment stage of the European process, with formal authorization resting with the Commission. The recommendation covers children under 24 months who face an increased risk of severe RSV infection and would extend protection through a second RSV season.
European Commission Decision Expected Within Two Months
The European Commission will now review the CHMP's recommendation before deciding whether to authorize the expanded indication, and Merck expects a final decision within two months. If approved, the expanded indication would apply across the European Union, Iceland, Liechtenstein, and Norway, since a single Commission decision takes effect in all four markets simultaneously.
The proposed approval would address children with underlying conditions that increase their vulnerability to serious respiratory illness, including chronic lung disease, congenital heart disease, and certain complications linked to premature birth. Children in these groups can develop severe RSV infections, such as pneumonia and bronchiolitis, during their second RSV season. Merck aims to extend preventive treatment beyond the first season for eligible children.
Phase 3 SMART Trial Data Underpin the European Application
Merck supported its European filing with data from the Phase 3 SMART clinical trial. The study assessed ENFLONSIA's safety, effectiveness, and drug exposure among children facing elevated risks of severe RSV disease, comparing the treatment with palivizumab during the first RSV season and then evaluating eligible children during a second season. The comparator choice carried practical weight, because palivizumab is given as monthly injections while ENFLONSIA is designed for a single dose per season.
During the first season, researchers assigned 502 participants to ENFLONSIA and 501 to monthly palivizumab injections. In total, 276 eligible children received an additional 210 mg dose of ENFLONSIA during their second RSV season, and most of these participants had chronic lung disease or congenital heart disease, reflecting the population targeted by the proposed expansion.
Merck presented the trial findings at the February 2026 RSVVW conference and published additional results in medical journals. The company previously secured U.S. Food and Drug Administration (FDA) approval for ENFLONSIA in June 2025 for infants entering their first RSV season. The European Commission followed with its approval in April 2026, extending the treatment's reach across European markets.
ENFLONSIA Approved in More Than 55 Countries
ENFLONSIA currently holds approvals in more than 55 countries, including the United States, Canada, China, and Japan. Unlike weight-based alternatives, the treatment uses a standard 105 mg dose for infants during their first RSV season. Its extended half-life monoclonal antibody design provides protection for approximately five months.
In the United States, Merck is seeking expanded authorization for high-risk children entering their second RSV season. The FDA has accepted the supplemental application and set March 22, 2027, as its target decision date. Meanwhile, Merck continues to pursue additional regulatory approvals across international markets as it works to broaden the reach of its RSV prevention portfolio.
The latest European recommendation marks another regulatory development for Merck's growing RSV prevention portfolio. Two dates now anchor the program's near-term regulatory calendar: the European Commission's decision expected within two months and the FDA's March 22, 2027 target for the parallel U.S. application. The expanded European indication still requires formal authorization from the European Commission before it can take effect. Merck shares ended the reported session higher, with the 0.65% gain recorded alongside the regulatory announcement.
Source: Blockonomi